Emcure Pharmaceuticals' Q1 FY 2025-26 Quarterly Results

Result Summary

• Emcure Pharmaceuticals Ltd reported a 18.0% quarter-on-quarter (QoQ) increase in its consolidated revenues for the quarter-ended Jun (Q1 FY 2025-26). On a year-on-year (YoY) basis, it witnessed a growth of 14.4%.
• Its expenses for the quarter were up by 12.0% QoQ and 11.0% YoY.
• The net profit increased 77.5% QoQ and increased 40.8% YoY.
• The earnings per share (EPS) of Emcure Pharmaceuticals Ltd stood at 10.9 during Q1 FY 2025-26.

Financial Statments for Q1 FY 2025-26

Data Source: BSE, Company announcements The securities quoted are exemplary and are not recommendatory. Past performance is not indicative of future results

Company Overview

Emcure Pharmaceuticals Ltd is a prominent player in the pharmaceutical industry, primarily engaged in the development, manufacturing, and marketing of a broad range of pharmaceutical products. The company is renowned for its strong presence in the Indian market and has been expanding its international footprint. Emcure specializes in various therapeutic areas, including cardiology, oncology, nephrology, and anti-HIV medications. The company has been focusing on innovation and research to enhance its product portfolio and meet the evolving healthcare needs. As of the latest updates, there are no specific major developments reported for Emcure Pharmaceuticals Ltd.

Revenue

In the first quarter of fiscal year 2026 (Q1FY26), Emcure Pharmaceuticals Ltd reported total income of ₹2104.23 crores. This marks an increase from the previous quarter (Q4FY25), where total income was ₹1783.10 crores, reflecting a quarter-over-quarter (QoQ) growth of 18.0%. Compared to the same quarter in the previous fiscal year (Q1FY25), where the total income was ₹1838.58 crores, the company achieved a year-over-year (YoY) growth of 14.4%. These figures indicate a strong upward trend in revenue generation, signaling effective strategies in expanding market presence and possibly enhancing product offerings.

Profitability

The profitability of Emcure Pharmaceuticals Ltd saw significant improvement in Q1FY26. The profit before tax (PBT) increased to ₹290.76 crores from ₹166.90 crores in Q4FY25, representing a substantial QoQ growth of 74.2%. On a YoY basis, the PBT grew by 40.2% from ₹207.41 crores in Q1FY25. After accounting for taxes, the profit after tax (PAT) for Q1FY26 stood at ₹214.79 crores, up from ₹121.02 crores in Q4FY25, showcasing a robust QoQ growth of 77.5%. Compared to Q1FY25, where PAT was ₹152.59 crores, the YoY growth was 40.8%. This indicates a notable enhancement in the company's profitability margins.

Operating Metrics

The operating metrics of Emcure Pharmaceuticals Ltd demonstrate a consistent improvement. Total expenses for Q1FY26 were ₹1809.98 crores, which is higher than the ₹1616.05 crores reported in Q4FY25, a QoQ increase of 12.0%. When compared to Q1FY25's total expenses of ₹1631.17 crores, there is a YoY rise of 11.0%. The earnings per share (EPS) for Q1FY26 was ₹10.90, up from ₹6.40 in Q4FY25, marking a significant QoQ increase of 70.3%. From a YoY perspective, EPS rose from ₹8.00 in Q1FY25, demonstrating a growth of 36.3%. These metrics suggest effective cost management and improved operational efficiency contributing to the company's financial health.